Breaking News

Piramal’s Mumbai Facility Gains Indian GLP Certification

By Kristin Brooks | March 27, 2014

Areas of toxicity, mutagenicity, analytical and clinical chemistry testing in compliance

Piramal Enterprises Ltd.’s R&D facility in Goregaon, Mumbai, has received GLP Compliance Certification from the National GLP Compliance Monitoring Authority (NGCMA), Government of India. The certification covered areas of toxicity, mutagenicity, analytical and clinical chemistry testing, as well as hERG, bioanalysis and toxicokinetic evaluation.
The Goregaon facility provides drug discovery and development of New Chemical Entities (NCE) in the area of oncology and metabolic disorders.
Dr. Owe Owar, president of NCE Research, Piramal Enterprisessaid, "The GLP certification is a testament to high quality research through thorough SOP-driven Good Laboratory Practices, competent well-trained personnel and systematic documentation at Piramal's NCE R&D facility in Mumbai. Piramal's NCE R&D unit is committed to realize its mission towards serving patients globally with medicines that matter."

Related Compliance:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.